Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Thrombosis and Haemostasis

• Publication date

  2009-03-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH08-07-0451PMID 19350131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder

  2008cited by this paper
• The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.

  2008cited by this paper
• Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

  2007cited by this paper
• Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders

  2007cited by this paper
• Cerebral venous thrombosis: an update

  2007cited by this paper
• JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis

  2007cited by this paper
• The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype

  2007cited by this paper
• JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation

  2007cited by this paper
• The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis

  2007cited by this paper
• Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617F

  2007cited by this paper
• Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis

  2006cited by this paper
• Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

  2005cited by this paper
• Pathology and genetics: Tumours of haematopoietic and lymphoid tissues

  2001cited by this paper
• Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.

  1999cited by this paper
• Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.

  1995cited by this paper

• Budd–Chiari syndrome/hepatic venous outflow tract obstruction

  2018cites this paper
• Correlations of iodide ions with vascular endothelial growth factor and its receptors during the proliferation of vascular endothelial cells.

  2014cites this paper
• Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk‐guided management

  2013cites this paper
• Unusual thrombosis and thrombophilia A difficult problem to approach. Experience of four years

  2013cites this paper
• Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)

  2013cites this paper
• Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

  2012cites this paper
• Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

  2012cites this paper
• JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis

  2012cites this paper
• Thrombose de la veine porte et de la veine mésentérique supérieure : étude rétrospective de 88 cas

  2012influential citation
• Polycythemia vera: gender-related phenotypic differences

  2012cites this paper
• Meta‐analysis: the significance of screening for JAK2V617F mutation in Budd–Chiari syndrome and portal venous system thrombosis

  2011cites this paper
• JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis

  2011cites this paper
• Philadelphia-negative myeloproliferative Neoplasien

  2011cites this paper
• 13. Budd-Chiari Syndrome – Hepatic Venous Outflow Tract Obstruction

  2010cites this paper
• The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto‐splenomesenteric venous thrombosis

  2010cites this paper
• Kdy vyšetřit trombofilní stav a interpretovat výsledky

  2009cites this paper